Cencora, Inc.
COR · Drug Wholesalers · $58.9B
Turning up
Not on a screen at the moment — no base, so no pivot to draw. The price and volume are below.
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
The read
Cencora, Inc. is not on any of the screens right now. Its relative strength rating is 45, and it sits in Drug Wholesalers.
Peers
Catalyst roadmap
Nothing dated in the next three months that we can ingest automatically.
Flagged by the market sweep
Nothing flagged for this company on the last market sweep.
In the news
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · 1 day agoAbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · 5 days agoAmgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · 8 days agoHere's Why You Should Retain Cencora Stock in Your Portfolio for NowZacks Investment Research · 2026-09-04AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · 2026-09-04Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research · 2026-09-04
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray